Pilot Study RCT: EPO Vs Placebo in Primary Progressive MS

• Research type

  Research Study

• Full title

  A pilot single-centre, doubled blinded randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.

• IRAS ID

  5738

• Contact name

  Mike Boggild

• Sponsor organisation

  Walton Centre for Neurology and Neurosurgery NHS Trust

• Eudract number

  2008-005125-11

• ISRCTN Number

  0

• Clinicaltrials.gov Identifier

  0

• Research summary

  A pilot randomised controlled trial to assess and quantify the effect of recombinant human erythropoietin versus placebo, in patients with primary progressive multiple sclerosis. A recent uncontrolled study of this agent in progressive MS suggested significant improvements in disability in this patient group (Ehrenreich H et al 2007). The aim of this pilot study is to generate further controlled data in order to inform a possible larger trial. There is currently no licenced disease modifying treatment for primary progressive multiple sclerosis, therefore research in this area is imperative. rhEPO, as a licenced product (for anaemia in renal failure and malignancy), offers an appealing possible therapy in this patient group.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  08/H1010/76

• Date of REC Opinion

  29 Oct 2008

• REC opinion

  Further Information Favourable Opinion